A combinatorial strategy for treating KRAS mutant lung cancer
Therapeutic targeting of KRAS-mutant lung adenocarcinoma represents a major goal of clinical oncology. KRAS itself has proven difficult to inhibit, and the effectiveness of agents that target key KRAS effectors has been thwarted by activation of compensatory or parallel pathways that limit their eff...
Main Authors: | Manchado, Eusebio, Weissmueller, Susann, Morris, John P., Chen, Chi-Chao, Wullenkord, Ramona, Lujambio, Amaia, de Stanchina, Elisa, Poirier, John T., Gainor, Justin F., Corcoran, Ryan B., Engelman, Jeffrey A., Rudin, Charles M., Rosen, Neal, Lowe, Scott W. |
---|---|
Format: | Online |
Language: | English |
Published: |
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939262/ |
Similar Items
-
The usual SASPects of liver cancer
by: Lujambio, Amaia, et al.
Published: (2015) -
Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers
by: Ebi, Hiromichi, et al.
Published: (2014) -
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
by: Pang, Xiufeng, et al.
Published: (2016) -
DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2
by: Poirier, John T., et al.
Published: (2015) -
KRAS mutant colorectal tumors: Past and present
by: Brand, Toni M., et al.
Published: (2012)